Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $14.50.

A number of equities analysts have commented on the company. HC Wainwright reissued a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th.

Agenus Price Performance

Shares of AGEN stock opened at $2.98 on Thursday. The stock’s fifty day simple moving average is $3.49 and its 200 day simple moving average is $4.09. Agenus has a one year low of $1.38 and a one year high of $7.34. The firm has a market cap of $101.35 million, a price-to-earnings ratio of -1.40 and a beta of 1.62.

Agenus (NASDAQ:AGEN) last announced its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The company had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million. On average, research analysts anticipate that Agenus will post -12.55 earnings per share for the current year.

Institutional Trading of Agenus

Several hedge funds have recently modified their holdings of AGEN. Catalyst Funds Management Pty Ltd bought a new position in Agenus in the 2nd quarter worth approximately $50,000. Jump Financial LLC bought a new stake in shares of Agenus during the second quarter worth $55,000. Traynor Capital Management Inc. bought a new stake in shares of Agenus during the third quarter worth $50,000. R Squared Ltd acquired a new position in shares of Agenus during the fourth quarter valued at $41,000. Finally, CWM LLC boosted its holdings in Agenus by 105.8% in the second quarter. CWM LLC now owns 26,246 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 13,494 shares during the last quarter. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.